Revolutionizing Soft Tissue Repair
Present Status & Key Achievements
Nurami was established in 2014 and raised over $1.5M since then. Nurami is also supported financially by the Israeli Innovation Authority and by NGT3 Venture fund.
Major preclinical trials are completed and clinical trials are planned to start beginning of 2018.
Nurami seeks funding to complete clinical trials for CE and FDA approvals and to continue development of pipeline projects.
Our vision is to implement Nurami’s innovative nanofiber technology in a variety of soft tissue repair products and become a major player in next-generation surgery